A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer

Model scores of the 29,894 trials active now.

Model score 17% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lung cancernsclccell lungsmall cellnon small
  Phrases that lowered it: participantsstudy willvegfbodydrugs
• Sponsor's past termination rate: 5.0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 182 (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 24.5% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 96.0% (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Sponsor's past trials: 738 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 5108 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin NCT00981058 · started 2010 · scored riskier than 38% of active trials completed
• A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC NCT02392507 · started 2015 · scored riskier than 21% of active trials completed
• A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer NCT01769391 · started 2013 · scored riskier than 57% of active trials completed
• A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before NCT00870870 · started 2009 · scored riskier than 40% of active trials completed
• First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin NCT00982111 · started 2009 · scored riskier than 26% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.